Putin, Erdogan may have telephone conversation soon — KremlinRussian Politics & Diplomacy September 20, 21:39
Lavrov offers condolences to Mexican people over deadly earthquakesRussian Politics & Diplomacy September 20, 21:01
UN Security Council passes resolution on peacekeeping reformWorld September 20, 20:14
UN peacekeepers should use force only for self-defense — LavrovRussian Politics & Diplomacy September 20, 20:01
Breaking of Idlib siege leaves three Russian servicemen woundedMilitary & Defense September 20, 19:00
Ukraine's president requests UNSC to deploy UN mission to Donbass as soon as possibleWorld September 20, 18:30
Diplomat believes Morgan Freeman was 'roped in' to be weaponized in anti-Russia crusadeRussian Politics & Diplomacy September 20, 18:02
Russian lawyer blasts ‘medieval’ efforts by UK Paralympic athletes to fake handicapSport September 20, 17:36
Aftermath of powerful earthquake in MexicoWorld September 20, 17:28
TOKYO, April 16, 2014 /PRNewswire/ -- Ajinomoto Pharmaceuticals Co., Ltd. announced on April 16 that the abstract of phase 2a clinical study data of an oral alpha 4 integrin antagonist, development code AJM300, has been accepted for presentation at the Digestive Disease Week 2014 (May 3 - 6 in Chicago, USA). The contents of data will be presented at the beginning of Joint Presidential Plenary Session collaborated by the American Society for Gastrointestinal Endoscopy and the American Gastroenterological Association.
- Study data to be presented (Presentation date / time: USA Eastern time zone)
Abstract No.: 370
Title: AJM300, an Oral alpha 4 Integrin Antagonist, for Active Ulcerative Colitis: a Multicenter, Randomized, Double-Blind, Placebo- Controlled* Phase 2A Study
Presentation date / time: May 4, 2014, 1:36-1:46 PM, Oral presentation
*Randomized double-blind, placebo-controlled study
Randomized double-blind, placebo-controlled study is a method of study to objectively evaluate the efficacy of medicine. In the study, neither investigators nor patients know which the patient takes a placebo (a mimic preparation that looks like a study drug but contains no active ingredient) or the study drug.
About Ajinomoto Pharmaceuticals Co., Ltd.
Representative Director,President & CEO: Takashi Nagamachi
Headquarters, Chuo-ku, Tokyo
Hajime Ito, Corporate Planning Dept, Ajinomoto Pharmaceuticals Co., Ltd.